AVROBIO, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 24.96 million compared to USD 29.83 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.68 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.47 USD | -0.12% | -3.17% | +0.92% |
06-20 | Avrobio Closes Merger With Tectonic Therapeutic | MT |
06-20 | Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.92% | 243M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- AVRO Stock
- News Tectonic Therapeutic, Inc.
- AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023